Abstract
5-methyltetrahydrohomofolate was developed in the 1970's as an antifolate with the potential to overcome methotrexate resistance. This review summarizes the preclinical and clinical data which have accumulated to date. It is concluded that more recent, better characterized antifolates offer greater potential in achieving the goals for which this drug was introduced.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Schornagel JH, McVie JG: The clinical pharmacology of methotrexate. Cancer Treat Rev 10:53–75, 1983
Roth B, Cheng CC: Recent progress in the medicinal chemistry of 2,4-diaminopyrimidines. Prog Med Chem 19:269–331, 1982
Kim YH, Grubliauskas V, Friedman OM: An improved synthesis of homopteroic and homofolic acids (1–3). J Het Chem 9:481–487, 1972
Goodman L, DeGraw H, Kisliuk RL, Friedkin M, Pastore EJ, Crawford EJ, Plante LT, Al-Nahas A, Morningstar JF, Kwok G, Wilson L, Donovan F, Ratzan J: Tetrahydrohomofolate, as specific inhibitor of thymidylate synthetase. J Amer Chem Soc 86:308–309, 1964
Kisliuk RL, Gaumont Y: Action of diastereoisomers of tetrahydrohomofolate on the growth of Latobacillus Casei. Ann NY Acad Sci 186:438–440, 1971
Kisliuk RL, Faumont Y: d, L-Tetrahydrohomofolate: A growth inhibitor. (Abstr) Fed Proc Fed Amer Soc Exp Biol 99:807, 1970
Mishra LC, Mead JAR: Further evaluation of the antitumor activity of homofolate and its reduced derivatives against methotrexate insensitive tumor. Chemo (Basel) 17:283–292, 1972
Mishra LC, Parmar AS, Mead JAR: Reduction of dihydrohomofolate (DHR) to tetrahydrohomofolate (THF) and its physiological disposition in rhesus monkey. Fed Proc Fed Amer Soc Exp Biol 32:777, 1973
Mishra LC, Parmar AS, Mead JAR, Knott R, Taunton-Rigby A, Friedman OM: Comparative antitumor activity of 5-methyltetrahydrohomofolate (Ch3H4HF) and tetrahydrohomofolate H4HF) in mice. (Abstr) Proc Amer Assoc Cancer Res 13:76, 1972
Goldman ID, Bailey BD, White JC, Lawrence W: Demonstration of a second transport route for tetrahydrofolates in the Ehrlich ascites tumor with 5-CH3-H4-homofolate. (Abstr) Proc Amer Assoc Cancer Res 18:80, 1976
Jayme DW, Kumar PMH, Rao NA, North JA, Mangum JH: The interaction of antitumor drugs with folate-requiring enzymes. Proc Miami Winter Symp 12:340, 1976
Hoffman RM: Altered methionine metabolism, DNA methylation and oncogene expression in carcinogenesis: A review and synthesis. Biochem Biophys Acta 738:49–87, 1984
Hoffman RM, Jacobsen S, Erbe RW: Reversion to methionine independence in simian virus 40-transformed human and malignant rat fibroblast is associated with altered ploidy and altered properties of transformation. Proc Natl Acad Sci USA 76:1313–1317, 1979
Hoffman RM, Jacobsen S: Reversion to methionine independence by malignant rat and SV 40-transformed human fibroblasts. Biochem Biophys Res Commun 82:228–234, 1978
El Dareer SM, Tillery KF, Hill DL: Disposition of 5-methyltetrahydrohomofolate in mice, dogs and monkeys. Cancer Treat Rep 63:201–207, 1979
El Dareer SM, Tillery KF, Hill DL: Disposition of 5-methyltetrahydrohomofolate and methotrexate in rats. Cancer Treat Rep 65:101–106, 1981
Loo TL, Juishi L, Lu K, Savaraj N: Clinical pharmacokinetics of 5-methyltetrahydrohomofolate. Cancer Res 43:921–924, 1983
Cohen GI, Parker LM, Rosowsky A, Ervin TJ, Modest EJ, Frei III E: 5-methyltetrahydrohomofolate (MTHHF): Phase I trial and pharmacology in man. (Abstract) Proc Am Soc Clin Oncol 1:14, 1982
Huennekens FM: Folate antagonists in chemotherapy. Natl Cancer Inst Monogr 1987, in press
Jackson RC, Grindey GB: The biochemical basis for methotrexate cytotoxicity. In: Sirotnak FM (ed) Folate Antagonists as Therapeutic Agents, Academic Press, New York, 1984, pp 43–95
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
O'Dwyer, P.J., Wagner, B.H., Hoth, D.F. et al. 5-methyltetrahydrohomofolate. Invest New Drugs 5, 215–218 (1987). https://doi.org/10.1007/BF00175290
Issue Date:
DOI: https://doi.org/10.1007/BF00175290